Phase I-II


Related News

Avoca CEO Patricia Leuchten on stage at the Avoca Quality Consortium (AQC) summit.

Pace of change in clinical trial landscape has become rapid, says Avoca CEO

The First-in-Human trial demonstrated that the novel challenge agent had high attack rates of up to 100%. (Image: iStock/bodym)

SGS completes Ph I trial of new influenza virus

CRO turnover increased from 20.1% in 2015 to 22% last year. (Image: iStock/PhotoProdra)

Report: CRO turnover creates loss of continuity

See More Headlines